Genetic basis for hypertrophic cardiomyopathy: implications for diagnosis and treatment.
Familial hypertrophic cardiomyopathy is a genetic disease defined by cardiac hypertrophy in the absence of an increased external load. It is the most common inherited cardiac disorder occurring in 1 in 500 individuals. Ten genes exhibiting over 200 mutations have been identified. However, about 75% are due to mutations in just three genes: e-myosin heavy chain, cardiac troponin T, and myosin binding protein-C. Certain phenotypes are more common with certain genes, such as the myosin binding protein-C gene, which induces the disease predominantly in the fifth or sixth decade of life. Genetic animal models in the mouse and rabbit have helped to elucidate the pathophysiology. The primary defect imparted by the specific mutation alters contractile function, which stimulates release of various growth factors that induce secondary cardiac hypertrophy and fibrosis. Placebo single-blinded studies in the mouse indicate that losartan reverses the phenotype; in the rabbit, simvastatin essentially reversed the phenotype after 12 weeks of therapy. Clinical trials are ongoing in human familial hypertrophic cardiomyopathy.
Roberts
Robert
R
Department of Medicine, Section of Cardiology, Baylor College of Medicine, Houston, TX 77030, USA. rroberts@bcm.tmc.edu
Sidhu
Jasvinder
J
D000818:Animals; D002312:Cardiomyopathy, Hypertrophic / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics*; D005820:Genetic Testing; D005838:Genotype; D006801:Humans; D008967:Molecular Biology; D009154:Mutation; D010641:Phenotype